Montréal Startup seeks to convey tests for a biopsy of liquid biopsy to patients with Quebec outside the main centers.
The biotechnological startup, which creates quick testing of cancer screening, is united with the organization Québec in order to increase its presence in the province.
Montreal Boring He collaborates with a private medical clinic Genoscience to expand access to advanced cancer testing in more than 50 places in Quebec. Cooperation will allow non -invasive tests for the Avitia liquid biopsy to detect cancer in more patients outside the largest cities in the province.
“Most countries and most provinces in Canada realized that everything that, especially in the world after Kovida, can reduce the load on the hospital infrastructure.”
The biotechnological startup offers genetic screening for cancer mutations on the spot through a blood test, which eliminates the need for cancer centers for sending laboratory tests to third parties, which can be expensive and laborious. His program platform analyzes genetic screening data to determine the presence of blood cancer, and then uses machine learning to compare patients with a list of potential treatment methods.
James Lamsalein, co -founder and general director of Avitia, said in an interview with Betakit that the partnership continues to grow a startup throughout Canada in order to provide access to more patients.
“You retain everything that directly affects the patient in a very convenient radius, so that the influence on their life is minimized,” Lumsdin said.
Liquid biopsy is a less invasive alternative to tissue biopsy, which was traditionally used for cancer screening. Avitia uses the next generation sequencing (NGS) to identify mutation causing cancer in the patient genome. The popularity of NGS in the diagnostic space of cancer has grown over the past decade, since the technique has become more affordable and effective.
Avitia claims that its technology was used in more than 40,000 cancer diagnostics tests performed by its partners. LumsDaine said that Avitia liquid biopsy is available only for a private system. He argued that some provinces of Canada are increasingly studying compensation for liquid biopsy in the social system.
Nevertheless, LumsDaine argued that the cost is lower than for some private competitors and varies depending on the location of this partner, logistics and delivery. LumsDaine refused to provide a number, but the Canadian Company MDETect colleague provides early lung cancer tests for about $ 500. California Biotechnological Company Grail offers its galleries Blood testing cancer For $ 2100 in a clinic in Toronto.
“We are actively working to reduce barriers to compensation and guarantee that the cost is never worth between the patient and the care that they deserve,” said Martin Landry General Director.
CONNECTED: Tatum Bioscience leads to a scalable cancer vaccine
LumsDaine said that Avitia seeks to improve its product offer, expanding its information platform, which processes blood markers and gives recommendations. He also develops a specific product suitable for diagnosing endometrial cancer and uterus, which disproportionately affects Colored women And those of the lower Socio -economic backgroundsField
The financial burden of cancer and treatment in Canada on average is $ 33,000. Canadian oncological societyField
Preventive tests, including fluid biopsy, can catch cancer earlier and lead to the best results, according to American Cancer Research InstituteA field in Canada, the Federal Minister of Health ordered to revise the national Target group for preventive medical careAffirming that many guiding principles on the usual screening of general cancer were outdated.
“Most countries and most provinces in Canada realized that everything that, especially in the world after Kovida, can reduce the burden on hospital infrastructure,” Lumsdin said.
Avitia launched her Diagnostic cancer platform Earlier this year – with assets of intellectual property Now does not exist Imagia Canexia Health – and attracted 5 million US dollars for seed funding. CANEXIA (previously contextual genomics) was founded in 2012 to develop genetic screening tests for the selection of cancer treatment and diseases monitoring. Kanexia combined With IMAGIA, a provider of digital medical decisions, focused on data privacy, in 2022.
LumsDaine refused to income. He said that Avitia has a trace in most Canada and will launch international partnerships in the Middle East and Southeast Asia until the end of this year, following a similar model with the Genoscency partnership.
The image is provided by avitia through LinkedinField
